Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

Watanabe,Hiroko; Tamura,Tomohiro; Kagohashi,Katsunori; Takayashiki,Norio; Kurishima,Koichi; Satoh,Hiroaki; Hizawa,Nobuyuki

doi:10.3892/etm.2015.2499

July-2015 Volume 10 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2015 Volume 10 Issue 1

Full Size Image

Case Report

Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

Authors:
- Hiroko Watanabe
- Tomohiro Tamura
- Katsunori Kagohashi
- Norio Takayashiki
- Koichi Kurishima
- Hiroaki Satoh
- Nobuyuki Hizawa
View Affiliations / Copyright

Affiliations: Division of Respiratory Medicine, Department of Clinical Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Pathology, Department of Clinical Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Respiratory Medicine, Department of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukiba, Ibaraki 305‑8575, Japan
Pages: 386-388
|
Published online on: May 18, 2015

https://doi.org/10.3892/etm.2015.2499
Expand metrics +

Abstract

Epidermal growth factor receptor (EGFR) mutation is a favorable prognostic factor of non-small cell lung cancer (NSCLC). In the majority of patients with EGFR mutations, clinical benefits of EGFR‑tyrosine kinase inhibitors (TKIs) have been reported. One of the TKIs, gefitinib, appears to be less toxic to the skin than other TKIs. The present study reports a case of NSCLC with EGFR mutation (exon 19 deletion) in which dose‑reduced gefitinib was effective against recurrence. Due to development of a grade 3 skin adverse event (AE) after 2 months of daily administration of gefitinib, the frequency of administration of gefitinib was reduced to every other day for 2 weeks. As the AE continued, the frequency of administration was reduced to once every 3 days. The patient has been in remission for 27 months since treatment with 250 mg gefitinib once every 3 days was initiated, which is the lowest dose to be reported in a successfully treated case of NSCLC with EGFR mutation. Dose reduction of gefitinib might be appropriate for patients with severe AEs and should be considered as a treatment option after 1 or 2 months of regular daily dosing of gefitinib if there is no other satisfactory treatment option.

View Figures

View References

1	Yang CH: EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: Present and future. Lung Cancer. 60:(Suppl 2). S23–S30. 2008. View Article : Google Scholar : PubMed/NCBI
2	Sanford M and Scott LJ: Gefitinib: A review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs. 69:2303–2328. 2009. View Article : Google Scholar : PubMed/NCBI
3	Hanaoka T, Sone S, Yamaguchi S, Okada M and Hayano T: An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib. Gan To Kagaku Ryoh. 34:1701–1703. 2007.(In Japanese).
4	Tomisaki S, Takenaka T, Morizono G, Tanaka T, Momosaki N and Inoue F: Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy. Gan To Kagaku Ryoho. 36:2607–2610. 2009.(In Japanese). PubMed/NCBI
5	Kitamura Y, Sakakura N, Uchida T and Suyama M: Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case. Gan To Kagaku Ryoho. 38:275–277. 2011.(In Japanese). PubMed/NCBI
6	Sato S, Kurishima K, Miyazaki K, Kodama T, Ishikawa H, Kagohashi K, Tamura T, Homma S, Satoh H and Hizawa N: Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area. Mol Clin Oncol. 2:604–608. 2014.PubMed/NCBI
7	McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N and Stephens TC: Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther. 4:641–649. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wang S, Zhou Q and Gallo JM: Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 8:1438–1447. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H and Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol. 20:2240–2250. 2002. View Article : Google Scholar : PubMed/NCBI
10	Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP and Fukuoka M: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 14:922–930. 2003. View Article : Google Scholar : PubMed/NCBI
11	Wolf M, Swaisland H and Averbuch S: Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy. Clin Cancer Res. 10:4607–4613. 2004. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles